文献速递类风湿关节炎脊柱关节炎

炎症性关节炎患者接受DMARDs治疗时乙肝病毒再激活风险的系统综述与Meta分析

Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2018-04-12

该系统综述与Meta分析评估了已消退或慢性HBV感染的炎症性关节炎患者接受DMARDs治疗时HBV再激活率,无论是否使用抗病毒预防。结论认为已消退患者再激活率低,慢性感染者中等,抗病毒预防可降低再激活率。

要点

  • 已消退HBV的炎症性关节炎患者接受DMARDs后HBV再激活率低(1.6%)。
  • 慢性HBV感染患者接受抗病毒预防者再激活率低于未预防者。
  • 非TNF生物制剂组再激活率数值较高但置信区间宽,需谨慎解读。

核心结论

  • 炎症性关节炎患者接受DMARDs时,已消退HBV感染者HBV再激活率低,慢性HBV感染者中等,抗病毒预防可降低慢性感染者的再激活率。

研究设计与样本

  • 纳入标准为类风湿关节炎、银屑病关节炎、强直性脊柱炎患者,且为已消退或慢性HBV感染,干预为TNF抑制剂或非TNF生物制剂或非生物DMARDs,结局为HBV再激活。
  • 四位评价者独立提取数据并使用Newcastle-Ottawa量表评估研究质量。
  • 采用Freeman-Tukey型反正弦平方根变换稳定原始比例的方差,并使用随机效应模型确定合并HBV再激活率。

主要发现

  • 已消退HBV患者总体合并HBV再激活率为1.6%(95%CI 0.8-2.6)。
  • 已消退HBV患者中,使用TNF抑制剂者再激活率为1.4%(95%CI 0.5-2.6),使用非TNF生物制剂者为6.1%(95%CI 0.0-16.6),使用非生物DMARDs者为1.7%(95%CI 0.2-4.2)。
  • 慢性HBV感染患者中,接受抗病毒预防者再激活率为9.0%(95%CI 4.1-15.5),未接受预防者为14.6%(95%CI 4.3-29.0)。

关键数值与推荐

  • 已消退HBV患者总体再激活率1.6%(95%CI 0.8-2.6)。
  • 已消退HBV患者使用TNF抑制剂再激活率1.4%(95%CI 0.5-2.6),非TNF生物制剂6.1%(95%CI 0.0-16.6),非生物DMARDs 1.7%(95%CI 0.2-4.2)。
  • 慢性HBV感染患者接受抗病毒预防者再激活率9.0%(95%CI 4.1-15.5),未接受者14.6%(95%CI 4.3-29.0)。

临床怎么用

  • 对炎症性关节炎患者启动DMARDs前应筛查HBV感染状态。
  • 对慢性HBV感染患者,考虑使用抗病毒预防以降低HBV再激活风险。
  • 已消退HBV患者接受DMARDs时再激活风险低,但仍需根据个体情况监测。

局限性

  • 非TNF生物制剂组的再激活率置信区间宽(0.0-16.6),提示估计不精确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess hepatitis B virus (HBV) reactivation rates in patients with resolved or chronic HBV infection, receiving disease-modifying antirheumatic drugs (DMARDs) and with or without antiviral prophylaxis. METHODS: We conducted a systematic review and meta-analysis. Electronic searches were conducted in PubMed, Medline, and Embase using Ovid through December 31, 2015. A search strategy was developed for each database using the following inclusion criteria: for participants, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and resolved or chronic HBV infection; for intervention, tumor necrosis factor (TNF) inhibitors or non-TNF biologic or nonbiologic DMARDs; and for outcome, HBV reactivation. Four reviewers independently extracted study data and assessed study quality using the Newcastle-Ottawa Scale. To determine the pooled HBV reactivation rate, the variances of the raw proportions were stabilized using a Freeman-Tukey-type arcsine square root transformation, using a random-effects model. RESULTS: Twenty-five studies met the inclusion criteria. The overall pooled rate of HBV reactivation was 1.6% (95% confidence interval [95% CI] 0.8-2.6) in patients with resolved HBV. Similar rates were observed in resolved patients taking TNF inhibitors (1.4% [95% CI 0.5-2.6]), non-TNF biologics (6.1% [95% CI 0.0-16.6]), and nonbiologic DMARDs (1.7% [95% CI 0.2-4.2]). We also found that the reactivation rate was lower in patients with chronic HBV infection who received antiviral prophylaxis (9.0% [95% CI 4.1-15.5]) than in those who did not (14.6% [95% CI 4.3-29.0]). CONCLUSION: We found that the HBV reactivation rate in inflammatory arthritis patients receiving DMARDs was low in resolved patients and moderate in patients with chronic HBV infection. Further, lower rates were observed in patients with chronic HBV infection who were using antiviral prophylaxis.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Lin TC, Yoshida K, Tedeschi SK, et al. Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2018. PMID: 28834412. doi:10.1002/acr.23346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。